Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

Femasys Inc. announced it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States, including prominent academic centers like Baylor Research Institute and Columbia University Medical Center. The expansion, enabled by August 2026 financing, demonstrates progress in the company's U.S. regulatory strategy for FDA approval of FemBloc, a non-surgical permanent birth control solution already approved in Europe, UK, and New Zealand.

Femasys Doubles Number Of Enrolling Facilities To 12 In Its FemBloc FINALE Pivotal Study Across U.S.

Femasys Announces Partnership With Fertility Financing Firm CapexMD To Offer Patient Financing For FemaSeed Fertility Portfolio; Terms Not Disclosed

Femasys Files Prospectus Related To The Offer And Resale From Time To Time By The Selling Stockholders Of Up To An Aggregate Of 28,124,997 Shares Of Common Stock

https://www.sec.gov/Archives/edgar/data/1339005/000114036126035625/ny20081537x1_s3.htm